DMT and the Brain: What Neuroscience Reveals

A short-acting molecule with a long research history

N,N-dimethyltryptamine (DMT) is a small tryptamine molecule related to serotonin. It is the visionary ingredient of ayahuasca and has been detected in mammals, including in the rat brain. (Scientific Reports, 2019) (Journal of Ethnopharmacology, 1999; Journal of Pharmacology and Experimental Therapeutics, 2003) When it is injected or inhaled, the experience it produces is unusually fast and unusually brief. That has made it attractive to neuroscientists who want to watch the brain move into and out of an altered state within a single scan.

This article covers what that research has and has not shown: the chemistry and pharmacology, the endogenous DMT question, the human studies from the 1990s to the 2026 EEG work, and the first depression trials. For the current evidence on psychedelics for depression in general, the psilocybin for depression page and the depression trials listing are the place to start. The DMT substance page has the basic profile.

How DMT acts: 5-HT2A and monoamine oxidase

Classic psychedelics, DMT among them, are agonists or partial agonists at serotonin 5-HT2A receptors, with receptors on the dendrites of layer V pyramidal cells in the cortex thought to matter most. (Pharmacological Reviews, 2016) DMT also binds the sigma-1 receptor, a protein involved in cell stress responses; in mice, DMT-induced hyperactivity was absent in animals bred without that receptor. (Science, 2009) In human stem-cell-derived neurons, DMT protected cells from severe oxygen deprivation through sigma-1. (Frontiers in Neuroscience, 2016) That is a dish result: no study has shown the same protection in a living human brain.

The body clears DMT very quickly. In a trial of a 10-minute intravenous infusion in 24 healthy adults, its elimination half-life was 9 to 12 minutes, and laboratory work showed it is broken down mainly by monoamine oxidase A (MAO-A), with CYP2D6 playing a smaller part. (European Journal of Drug Metabolism and Pharmacokinetics, 2023)

That breakdown explains ayahuasca. Swallowed on its own, DMT is destroyed in the gut and liver before it reaches the brain. Ayahuasca combines a DMT-containing plant with harmala alkaloids, harmine and harmaline, that reversibly inhibit MAO-A and let DMT through; the inhibition seems to act mainly in the gut and liver. (Journal of Ethnopharmacology, 1999; Journal of Pharmacology and Experimental Therapeutics, 2003) The same MAO inhibition is why ayahuasca combined with SSRI antidepressants may cause serotonin syndrome, and why ICEERS treats that combination as contraindicated. (Journal of Psychoactive Drugs, 1998; ICEERS, 2026) Inhaled or injected DMT does not need an MAO inhibitor, and the Brazilian researchers testing vaporised DMT argue that this lowers the interaction risk compared with ayahuasca. (Neuropsychopharmacology, 2025)

Endogenous DMT: what the evidence actually shows

Few psychedelic claims travel as far as the idea that the pineal gland floods the brain with DMT at birth, in dreams or at death. The evidence is narrower.

• In 2013 a Louisiana State and Michigan team reported, for the first time, DMT in fluid sampled by microdialysis from the pineal gland of living rats. (Biomedical Chromatography, 2013)
• In 2019 a University of Michigan team (Dean and colleagues, with Borjigin as senior author) found the gene for INMT, one of the two enzymes that make DMT, expressed in the cerebral cortex, pineal gland and choroid plexus of rats and humans. In rats, DMT levels in the cortex were similar to those of serotonin, with or without a pineal gland, and rose in the visual cortex after induced cardiac arrest, again whether or not the pineal was intact. (Scientific Reports, 2019)
• A 2018 review by Steven Barker, a co-author of both studies, calls for more work to establish DMT's role in the pineal gland and to separate any natural function from the effects of giving the drug. (Frontiers in Neuroscience, 2018)

So rats can make DMT in the brain, the pineal gland is not required for it, and a rise was measured in dying rats. Nobody has measured a rise in a dying human, and nobody has shown that the amounts made naturally are enough to produce psychedelic effects. The near-death and pineal theories remain hypotheses.

The Strassman studies

The first modern human DMT research was done by Rick Strassman at the University of New Mexico. In a double-blind, placebo-controlled study, 11 experienced hallucinogen users received intravenous DMT at four doses from 0.05 to 0.4 mg/kg. Blood levels and subjective effects peaked within 2 minutes and were negligible at 30 minutes. DMT raised blood pressure, heart rate, pupil size, body temperature and several stress hormones, dose by dose. (Archives of General Psychiatry, 1994)

The companion paper described the experience. Effects began almost at once, peaked at 90 to 120 seconds and had almost gone by 30 minutes. At the two higher doses volunteers reported a rush, a brief loss of control and fast-moving, brightly coloured visions, with euphoria alternating with anxiety; they rated the effects as more vivid than dreams or waking life. The team also introduced the Hallucinogen Rating Scale, still used in research. (Archives of General Psychiatry, 1994)

What brain imaging has found

Most of the recent imaging comes from Imperial College London.

EEG, 2019

In 13 volunteers, intravenous DMT sharply reduced alpha and beta brain rhythms compared with placebo and increased signal diversity, a measure of how varied the electrical activity is. Delta and theta rhythms emerged at the peak of the experience and tracked its closed-eye visual intensity. (Scientific Reports, 2019)

EEG with fMRI, 2023

In 20 healthy volunteers scanned with both techniques, DMT increased global functional connectivity, so that brain networks became less separate from each other. The areas whose connectivity changed most with rated intensity matched maps of 5-HT2A receptor density taken from separate PET data. (Proceedings of the National Academy of Sciences, 2023) You can read the study summary on the research page for that paper.

Moment-to-moment EEG, 2026

A 2026 study of 19 participants compared a medium and a high dose. Both changed experience rapidly; 40 mg gave more extreme visuals and more emotionally intense experiences. Alpha power and a measure called permutation entropy tracked moment-to-moment experience most closely, while Lempel-Ziv complexity, often cited as the signature of the psychedelic state, showed the weakest link. (Journal of Cognitive Neuroscience, 2026) That last finding is a useful caution against treating one complexity number as a readout of consciousness.

These are small studies of healthy volunteers. They show what the brain does during DMT, not why anyone might feel better afterwards.

Entity encounters

Many people describe meeting seemingly autonomous beings on DMT. A Johns Hopkins online survey of 2,561 people about their most memorable such encounter found the entity was most often labelled a being, guide, spirit, alien or helper. Although 41% reported fear, the strongest emotions were love, kindness and joy, and 69% said they received a message. More than half of those who were atheist beforehand no longer identified that way afterwards. (Journal of Psychopharmacology, 2020) The sample was self-selected, so these figures describe people who chose to answer, not DMT users in general.

Extended infusion: making a brief state last

Because a single dose lasts under 20 minutes, Andrew Gallimore and Rick Strassman proposed in 2016 adapting target-controlled infusion, a technique from anaesthesia, to hold people in a stable DMT state. (Frontiers in Pharmacology, 2016) Imperial tested a version in 11 healthy volunteers, pairing a loading dose with a slow infusion. Subjective effects held steady over 30 minutes, anxiety ratings stayed low and heart rate settled within 15 minutes. Plasma DMT kept rising while the experience plateaued, which the authors read as acute psychological tolerance. (Journal of Psychopharmacology, 2024)

DMT trials for depression

Registered and published depression trials of DMT do exist, but they are early.

• Intravenous DMT (SPL026), phase 2a. 34 adults with moderate to severe major depression were randomised to a single 21.5 mg infusion or placebo, with psychological support. At 2 weeks, depression scores (MADRS) fell 7.35 points more with DMT; in an open-label phase effects persisted up to 3 months. Adverse events were mostly mild to moderate and there were no serious ones. (Nature Medicine, 2026)
• Inhaled DMT, open-label. 14 patients with treatment-resistant depression received 15 mg then 60 mg. MADRS scores fell by an average of 21.1 points by day 7 with no serious adverse events, but there was no control group. (Neuropsychopharmacology, 2025)
• Healthy volunteers. Depression scores were lower 1 to 2 weeks after DMT in two small Imperial datasets. (Scientific Reports, 2024)
• Recruiting now. A 140-person randomised phase 2b trial of inhaled DMT for major depression is recruiting in Brazil, and a Basel trial is giving DMT under propofol anaesthesia to test whether the antidepressant effect needs the conscious experience at all. (ClinicalTrials.gov, 2026; ClinicalTrials.gov, 2025)

A 2025 systematic review of five early trials found rises in blood pressure and heart rate at higher intravenous doses that resolved quickly, and no serious adverse events, while noting how few trials there were. (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2025) Ayahuasca, the oral brew, has its own small randomised trial in treatment-resistant depression. (Psychological Medicine, 2019)

No DMT medicine is approved for depression anywhere. The psychedelic clinical trials listing shows recruiting studies.

Safety and the law

Even brief, DMT raises blood pressure and heart rate. (Archives of General Psychiatry, 1994) A systematic review of case reports of psychotic episodes after ayahuasca or DMT concluded that people with a personal or family history of psychotic illness or mania should avoid hallucinogens. (Therapeutic Advances in Psychopharmacology, 2017; ICEERS, 2026; ICEERS, 2018) Ayahuasca adds the MAO inhibition: anyone on an antidepressant or other serotonergic medicine should read the ayahuasca and antidepressants guide and check the interaction checker, and should talk to their prescriber rather than stop a medicine on their own.

DMT is listed in Schedule I of the US Controlled Substances Act. (Legal Information Institute (Cornell) reproducing the U.S. Code, current) Internationally it sits in Schedule I of the 1971 Convention on Psychotropic Substances. (United Nations Office on Drugs and Crime, 1971) Plants containing DMT, and brews such as ayahuasca made from them, are not under international control, although countries may control them nationally. (ICEERS, Oct 2023; International Narcotics Control Board, Mar 2011) People considering a ceremony abroad can compare the legal position and screening practices on the ayahuasca retreats hub.